Render Target: STATIC
Render Timestamp: 2025-01-21T12:55:15.244Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-09-20 06:18:09.982
Product last modified at: 2025-01-01T09:02:43.320Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

L-asparaginase/ASRGL1 Antibody #65552

Filter:
  • WB
Western Blotting Image 1: L-asparaginase/ASRGL1 Antibody
Western blot analysis of extracts from IGROV-1, Hep G2, and 293T cells using L-asparaginase/ASRGL1 Antibody.

To Purchase # 65552

Cat. # Size Qty. Price Ships
65552S 100 µl
$306 Jan 22

Supporting Data

REACTIVITY H R Mk
SENSITIVITY Endogenous
MW (kDa) 41
SOURCE Rabbit
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • H-Human 
  • R-Rat 
  • Mk-Monkey 

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

L-asparaginase/ASRGL1 Antibody recognizes endogenous levels of total L-asparaginase/ASRGL1 protein.

Species Reactivity:

Human, Rat, Monkey

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human L-asparaginase/ASRGL1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

L-asparaginase (ASRGL1) catalyzes the conversion of L-asparagine to L-aspartate. Research studies have shown that intracellular asparagine can suppress apoptosis in a large number of human tumors (1). In addition, acute lymphocytic leukemia cells frequently depend upon serum asparagine for their viability, as they lack asparagine synthetase (ASNS). Deprivation of asparagine by L-asparaginase has therefore been developed as a therapeutic treatment for acute lymphocytic leukemia (2-3). In KRAS mutant non-small cell lung carcinoma (NSCLC) cells, PI3K/Akt signaling was shown to be required for ASNS expression, suggesting combinatorial Akt inhibition and L-asparaginase treatment as a therapeutic strategy for NSCLC (3). Research studies on a breast cancer model have furthermore shown that restriction of asparagine can suppress cancer metastasis (4).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.